Hasil Pencarian - Djamila E. Issa

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015

    Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015 oleh Avinash G. Dinmohamed, Djamila E. Issa, Marjolein W.M. van der Poel, Harry C. Schouten, Pieternella J. Lugtenburg, Martine E.D. Chamuleau, Sonja Zweegman, Otto Visser

    Diterbitkan 2017-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands

    Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands oleh Elise R. A. Pennings, Müjde Durmaz, Otto Visser, Eduardus F. M. Posthuma, Djamila E. Issa, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    A high level of fatigue among long-term survivors of non-Hodgkin’s lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands

    A high level of fatigue among long-term survivors of non-Hodgkin’s lymphoma: results from the longitudinal population-based PROFILES registry in the south of the Netherlands oleh Simone Oerlemans, Floortje Mols, Djamila E. Issa, J. H. F. M. Pruijt, Wim G. Peters, Marnix Lybeert, Wobbe Zijlstra, Jan Willem W. Coebergh, Lonneke V. van de Poll-Franse

    Diterbitkan 2013-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989–2010

    Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989–2010 oleh Djamila E. Issa, Saskia A.M. van de Schans, Martine E.D. Chamuleau, Henrike E. Karim-Kos, Marielle Wondergem, Peter C. Huijgens, Jan Willem W. Coebergh, Sonja Zweegman, Otto Visser

    Diterbitkan 2015-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma

    Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma oleh Carolien C. H. M. Maas, David van Klaveren, Müjde Durmaz, Otto Visser, Djamila E. Issa, Eduardus F. M. Posthuma, Josée M. Zijlstra, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018

    Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018 oleh Müjde Durmaz, Otto Visser, Eduardus F. M. Posthuma, Rolf E. Brouwer, Djamila E. Issa, Daphne de Jong, King H. Lam, Nicole M. A. Blijlevens, Josée M. Zijlstra, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

    R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma oleh Diana Al-Sarayfi, Frederik O. Meeuwes, Müjde Durmaz, Djamila E. Issa, Rolf E. Brouwer, Aart Beeker, Anna van Rhenen, Pim G. N. J. Mutsaers, Lara H. Böhmer, Marjolein W. M. van der Poel, Liane te Boome, Tom van Meerten, Martine E. D. Chamuleau, Josée M. Zijlstra, Mirian Brink, Marcel Nijland

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    P1128: EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY

    P1128: EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY oleh Elise R.A. Pennings, Müjde Durmaz, Otto Visser, Eduardus F.M. Posthuma, Djamila E. Issa, Martine E.D. Chamuleau, Anne M. Spanjaart, Tom van Meerten, Pim G.N.J. Mutsaers, Margot Jak, Suzanne van Dorp, Joost S.P. Vermaat, Marjolein W.M. van der Poel, Maria T. Kuipers, Frederick W. Thielen, Carin A. Uyl-de Groot, Pieternella J. Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY

    P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE... oleh Kaz Groen, Claudia Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Niels W.C.J. van de Donk, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Mark-David Levin, Paula F. Ypma, Sonja Zweegman

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context

    Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context oleh Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Annelies Verbrugge, Danny Buitenhuis, Sonia M. Cunha, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Niels W.C.J. van de Donk, Mark-David Levin, Paula F. Ypma, Sonja Zweegman

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: